文献速递血栓与止血

获得性血友病A:艾美赛珠单抗时代的叙述性综述与管理策略

Acquired hemophilia A: a narrative review and management approach in the emicizumab era.
PubMed 文献 · J Thromb Haemost · 2024-11-12

本文综述获得性血友病A的流行病学、病理生理、诊断与治疗,整合注册研究、试验和病例系列数据,提出整合艾美赛珠单抗的标准化治疗算法,并强调关注免疫抑制相关死亡率。该算法为本机构常规做法,旨在减少止血产品使用和免疫抑制毒性,降低出血相关发病率与再住院率。

要点

  • 获得性血友病A由针对凝血因子VIII的抑制性自身抗体所致,治疗目标为清除抑制物和控制出血。
  • 艾美赛珠单抗作为因子VIIIa模拟双特异性抗体,在先天性血友病A获批后越来越多用于获得性血友病A。
  • 作者提出的分阶段治疗算法可在能快速进行一期法血浆因子VIII活性检测的中心实施。

核心结论

  • 近期注册数据提示获得性血友病A需关注免疫抑制相关死亡率,作者提出以算法格式的治疗推荐,旨在减少止血产品使用和免疫抑制治疗相关毒性,同时降低出血相关发病率和再住院率。

研究设计与样本

  • 叙述性综述,整合注册研究、试验和病例系列数据,并附一例病例说明诊断和管理考量。

主要发现

  • 获得性血友病A是一种由针对凝血因子VIII的抑制性自身抗体引起的罕见出血性疾病。
  • 治疗目标为双重:免疫抑制治疗以清除抑制物,以及止血管理以控制出血。
  • 艾美赛珠单抗是一种作为因子VIIIa模拟物的双特异性抗体,在先天性血友病A获批后用于获得性血友病A的情况日益增多。

关键数值与推荐

  • 作者提出的治疗算法包含按治疗阶段划分的关键干预措施,已成为本机构的常规做法。
  • 该算法可在能快速使用一期法检测血浆因子VIII活性的中心实施。

临床怎么用

  • 作者提出的治疗算法已成为本机构的常规做法,旨在减少止血产品使用和免疫抑制治疗相关毒性,同时降低出血相关发病率和再住院率。
  • 该算法可在能快速使用一期法检测血浆因子VIII活性的中心实施。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by inhibitory autoantibodies to factor (F)VIII. The goals of treatment are 2-fold, namely immunosuppressive therapy to eradicate the inhibitor and hemostatic management to control bleeding. Emicizumab, a bispecific antibody that acts as a FVIIIa-mimetic, has seen growing use in AHA following its approval for congenital hemophilia A. This review provides an overview of the epidemiology, pathophysiology, diagnosis, and treatment of AHA. Registry, trial, and case series data are assimilated and summarized with an emphasis on a standardized approach that integrates the use of emicizumab. With recent registry data suggesting the need to focus on immunosuppression-related mortality in AHA, we provide treatment recommendations in an algorithmic format that have become the standard of care at our institution. These recommendations are intended to minimize hemostatic product usage and potential toxicity related to immunosuppressive therapy while reducing morbidity and rehospitalization rates for bleeding. The proposed treatment algorithm, which includes key interventions by phase of therapy, can be readily implemented at centers that have rapid access to plasma FVIII activity using a one-stage assay. A case is presented to illustrate the proposed diagnostic and management considerations.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Ellsworth P, Chen SL, Jones LA, et al. Acquired hemophilia A: a narrative review and management approach in the emicizumab era. J Thromb Haemost. 2024. PMID: 39536818. doi:10.1016/j.jtha.2024.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。